Immune Thrombocytopenia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

  • Single User License $3500

Immune Thrombocytopenia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

Status : August, 2020 | Pharmaceutical | PPT format

Report Digest


Immune Thrombocytopenia Drugs Market: Overview

The autoimmune disorder of immune thrombocytopenia outcomes in an unusually low level of platelets. Asymptomatic bleeding disorders are immune thrombocytopenia. Only after platelet counts are exceptionally low appear symptoms. These are petechias, skin contusions, bleeding from the rubber gum, among others. While most of the ITP aren’t fatal cases, roughly 3 per cent die from complication like intracranial hemorrhages and infection in chronic refractory ITP patients. Most of the available ITP medicines are off-label medicines.

As a result of the growing demand for improved medical, the global immune thrombocytopenia industry has been experiencing stable development. Immune thrombocytopenia medicines are designated orphan by regulatory bodies with a high degree of pricing flexibility.

This market research report on the global immune thrombocytopenia drugs market encapsulates latest industry trends, market drivers, possible threats, and opportunities. The report discusses the competition landscape of the global immune thrombocytopenia drugs market in detail.

Immune Thrombocytopenia Drugs Market: Notable Developments

Some of the key developments that are expected to influence the global immune thrombocytopenia drugs market are:

  • New drug class, the TRAs, has been approved and the ITP treatment revolutionized in 2008. The approval of such novel drugs are expected to bode well for the global immune thrombocytopenia drugs market in coming years.
  • Rigel Pharmaceuticals, Inc. announced that it has signed an exclusive license and contract for the production of fostamatinib disodium hexahydrate to all prospective signs, both in Europe and in Turkey, with the company Grifols, S.A. This is expected to prove beneficial for the immune thrombocytopenia market growth.

Some of the most prominent competitors operating in the competitive landscape of global immune thrombocytopenia drugs market include –

  • Rigel Pharmaceuticals
  • Horizon Therapeutics Plc
  • Merck & Co.
  • CSL Ltd.
  • Amgen Inc.

Immune Thrombocytopenia Drugs Market Dynamics

Growing Awareness of Autoimmune Conditions to Spur Immune Thrombocytopenia Drugs Market

The ITP's secondary trigger are frequently autoimmune diseases, chronic infectios, medicines, pregnancies and certain cancers. The growing awareness of autoimmune conditions favors the growth of this market. The increased global incidence of ITP is largely boosting the immune thrombocytopenia drugs market. As a consequence, there will also be increased demand for therapy choices and medicines for cure of the immune system. Therefore, one of the major factors responsible for development of the industry is the high incidence of the related risk variables for immune thrombocytopenia. In addition, increased public efforts to enhance health infrastructure have had a positive impact on the worldwide ITP market, including in India, China and Brazil. Furthermore, enhanced concentration on the creation of new medicines and therapeutics has a beneficial effect on the market.

Exclusivity to Emerge as Key Market Trend

Orphan medicines may be exclusively regulated over several years, where abbreviated NDA/505(b) requests by another manufacturer are not submitted. This is expected to fuel the immune thrombocytopenia drugs market. In addition, orphan drugs have a 7-year period of exclusivity. Exclusiveness is aimed at promoting research and development investment by offering innovators with a restricted time exclusive use and the market for immune thrombocytopenia therapy. It works separately of the protection of the patent and protects the product against generic competition, even if the product does not have a patent and the development is anticipated to boost the immune thrombocytopenia drugs market to a large extent.

Global Immune Thrombocytopenia Drugs Market: Regional Analysis

The largest share of the ITP drug market will be reported in North America during the prediction period. The high incidence of related risk variables and the growing sale of authorized medications for immune thrombocytopenia therapy in North America will lead to the increase in the market for immune thrombocytopenia in the area.

The development of the economy is supported in Europe by several factors such as favorable public policies and high health spending. The existence of sophisticated healthcare facilities also stimulates the European market.

The study presents a granular assessment and quantitative evaluation of:

  • Key growth factors and prominent trends
  • Size and share of key segments in overall market
  • Key challenges and winning imperatives
  • Factors shaping competitive landscape
  • Insights into how contours of market will change in coming years
  • Technological advances
  • New avenues and imminent investment pockets
  • Regulatory landscape shaping current and future strategies of companies

The region-wise assessment includes market dynamics in:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study is prepared with the help of an extensive primary and secondary research. Primary research includes but not limited to interactions, interviews, surveys, and events. Opinions of policy makers and industry experts are carefully integrated into the insights to complement primary research. Volumes of secondary data gleaned through renowned paid sources, annual statements, reputed journals, and government documents offer insights into current dynamics and key evolution trajectories the market is likely to assume. The research employs various industry-wide analytics methods and well-established methodologies to ascertain the attractiveness of key segments. Further, it evaluates the lucrativeness of key regions and factors underlying their maturity. The insights notably include a detailed analysis of forces behind vendor differentiation and offers insight into investment-decision making by prominent players.

The report strives to enlighten businesses and industry stakeholders on multiple facets of the growth dynamic of the market, the key of which include answers to:

  • Which key factors will shape the competitive landscape?
  • Which trends will stimulate research and development activities in different geographies?
  • Which are the lucrative growth areas and what is the size of potential they are likely contribute to the overall market?
  • Which disruptions in market growth are likely to come with the new business models?
  • Which are some of the recent overhauls in policies that may change the course of the market significantly?
  • Which are the geographies that will form sizable sources of new streams to new and established players alike?
  • How are top players likely to realign their strategy to counter the forces of competition?
  • Which key strategies emerging players are likely to focus on to consolidate their position?
  • Which changes in end-user preferences might affect the status quo held by the leading players?
  • Which are some of the game-changing innovations influencing the projected share and revenue of the market and its segments?

Note: Utmost care has invariably been taken to present data and arrive at statistics at all the TMR Research reports. Meanwhile, some recent developments and new industry trends may take time to be included in the reports.